From: Clinical baseline factors predict response to natalizumab: their usefulness in patient selection
Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|
OR | CI | P | OR | CI | P | |
Sex (female vs male) | 2.31 | 0.57–9.32 | 0.24 | - | - | - |
Age | 1.00 | 0.94–1.07 | 0.88 | - | - | - |
Disease duration | 1.01 | 0.92–1.11 | 0.81 | - | - | - |
ARR in the pre-treatment year | 0.98 | 0.63–1.54 | 0.93 | - | - | - |
EDSS gain the pre-treatment year | 1.53 | 0.89–2.62 | 0.12 | - | - | - |
EDSS at baseline | 1.25 | 0.90–1.75 | 0.18 | - | - | - |
EDSS at baseline, categorized | 0.62 | - | - | - | ||
3.0 to 3.5 compared to < = 2.5 | 0.08 | 0.18–6.44 | 0.93 | - | - | - |
4.0 to 5.5 compared to < = 2.5 | 1.58 | 0.29–8.61 | 0.6 | - | - | - |
6 and above compared to < = 2.5 | 2.60 | 0.52–13.04 | 0.24 | - | - | - |
High pre-treatment disease activity | 4.12 | 1.05–16.23 | 0.04 | 4.12 | 1.05–16.23 | 0.04 |